Simpson Thacher recently represented the underwriters, led by J.P. Morgan Securities LLC, Cowen and Company, LLC, Piper Sandler & Co. and BMO Capital Markets Corp., in connection with the registered follow-on offering of 6,160,714 shares of Class A common stock by Nuvalent, Inc. (“Nuvalent”). The offering raised approximately $345 million in gross proceeds.
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
The Simpson Thacher team included Art Robinson, John O’Connell, Melissa Lewis, Aaron Gurley and Robert Bloomer (Capital Markets); Drew Purcell and Michael Mann (Tax); Vanessa Burrows, Nawa Lodin and Hilary Wong (Healthcare); Andrew Blau and Andrew O’Brien (ECEB); Michael Isby (Environmental); Corina Holland (IP); and Andrew Pagliughi (FINRA and Blue Sky).